← Back to Search

Monoclonal Antibodies

alirocumab for High Cholesterol

Phase 3
Waitlist Available
Led By Cara East, MD
Research Sponsored by Baylor Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 4, 8, 10, 12 weeks
Awards & highlights

Study Summary

This trial will test how well alirocumab works in patients with kidney disease who are on dialysis, and if it is safe for this population. Blood tests will be done to measure cholesterol and other markers. Safety events will be monitored throughout the study.

Eligible Conditions
  • High Cholesterol
  • Hemodialysis
  • Peritoneal Dialysis
  • Atherosclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 4, 8, 10, 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 4, 8, 10, 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in LDL cholesterol levels
Secondary outcome measures
Change in HDL-cholesterol levels
Change in apoprotein B levels
Other outcome measures
Change in PCSK9 levels
Change in alirocumab drug levels

Trial Design

1Treatment groups
Experimental Treatment
Group I: alirocumabExperimental Treatment1 Intervention
Alirocumab 150 mg q 2 weeks for 12 weeks

Find a Location

Who is running the clinical trial?

Baylor Research InstituteLead Sponsor
200 Previous Clinical Trials
203,206 Total Patients Enrolled
Regeneron PharmaceuticalsIndustry Sponsor
622 Previous Clinical Trials
380,711 Total Patients Enrolled
5 Trials studying High Cholesterol
888 Patients Enrolled for High Cholesterol
Cara East, MDPrincipal InvestigatorBaylor Research Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Alirocumab in Patients on a Stable Dialysis Regimen
2018. "Alirocumab in Patients on a Stable Dialysis Regimen". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03480568.
All > Dialysis
~3 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top